Every shopper wants to get more for their money. Furthermore, it makes no difference what the product is. Investors also favor doing it.
Granted, a low price doesn’t always equate to a good deal, whether we’re discussing stocks or cars. However, the price is still significant.
The good news is that investors in the current bear market have several excellent opportunities to obtain more for less. These two unstoppable stocks are available for less than $100 per share right now.
1. Walt Disney
Yes, the price of Walt Disney (DIS 2.69%) shares has fallen by over 40% so far this year. Mickey Mouse won’t be restrained for very long, though. With shares selling close to $93, Disney stock is now more accessible to regular investors than it has been in a while.
Moreover, the share price is not simply low for Disney. The stock’s price/earnings-to-growth (PEG) ratio of 0.6 makes the value of the entertainment behemoth extremely appealing. However, this PEG ratio predicts incredibly rapid growth over the upcoming few years. Can Disney deliver as promised? In my opinion.
It looks like the firm is thinking of combining its Disney+, Hulu, and ESPN+ streaming services. I think this approach would be fantastic because it may lower attrition and increase subscription growth.
Disney should succeed as long as people desire to be entertained. I don’t believe that human nature will alter.
2. Novocure
You may think it’s absurd of me to describe an unsuccessful biotech company as unstoppable. However, I firmly feel that the description applies to Novocure (NVCR -1.26%). Given that the stock has easily outperformed the market this year, many investors seem to be seeing promise in the business as well.
The tumor-treating fields (TTFields) from Novocure prevent tumor cells from dividing by using electrical fields. The business has previously received regulatory approval for TTFields to treat mesothelioma and glioblastoma, a type of brain cancer and a type of cancer caused by exposure to asbestos.
These signs only represent the very beginning. Early in 2023, Novocure intends to release findings from a late-stage study utilizing TTFields for the treatment of non-small cell lung cancer. Later on, in the coming year, results from two other late-stage studies focusing on brain metastases and ovarian cancer should be available. In 2024, the business anticipates releasing the findings of a new phase 3 study using TTFields to treat pancreatic cancer.
The price of shares right now is over $78. If the firm can secure more approvals for TTFields, and I believe it can, this stock won’t drop below $100 very soon. I believe the opportunity to purchase this game-changing stock at a bargain is rapidly approaching.
Comments are closed.